Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNA5 | P22460 | 6/20 | 0.47 |
| ▸ | HRH2 | P25021 | 7/20 | 0.46 |
| ▸ | HRH1 | P35367 | 7/20 | 0.46 |
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.46 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6738742 | 0.94 | HRH2 (0.45) | KCNA5HRH2HRH1HRH3CHRNA7 | |
| SCHEMBL6096450 | 0.89 | HRH2 (0.53) | KCNA5HRH2HRH1HRH3CHRNA7 | |
| SCHEMBL6740378 | 0.87 | HRH3 (0.42) | KCNA5HRH2HRH1HRH3CHRNA7 | |
| SCHEMBL2967829 | 0.86 | KCNH2 (0.48) | KCNA5HRH2HRH1HRH3CHRNA7 | |
| SCHEMBL6741203 | 0.86 | KCNJ1 (0.47) | CHRNA7ALDH1A1 | |
| SCHEMBL6741917 | 0.85 | HRH2 (0.44) | HRH2HRH1HRH3CHRNA7 | |
| SCHEMBL7477901 | 0.85 | KCNA5 (0.39) | KCNA5HRH2HRH1HRH3CHRNA7 | |
| SCHEMBL6995606 | 0.84 | HRH3 (0.49) | KCNA5HRH2HRH1HRH3KDM4E | |
| SCHEMBL7480678 | 0.84 | MMP2 (0.38) | KCNA5HRH2HRH1HRH3CHRNA7 | |
| SCHEMBL6739387 | 0.84 | KCNH2 (0.50) | KDM4ESMN1; SMN2ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040229900-A1 | Bispidine compounds useful in the treatment of cardiac arrythmias | ASTRAZENECA AB (SE) | 2004-11-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040229900-A1 | Bispidine compounds useful in the treatment of cardiac arrythmias | ADRA1B, ADRB2, ADRA1D | KCNA5 81/4885HRH2 113/4885HRH1 184/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.